FDA Clarifies Considerations for Botanical Combination Drugs

Clinical Trials Advisor
A A
The FDA updated its guidance for botanical drug development to include recommendations for navigating combination drug regulations, with possible criteria for receiving a waiver.

To View This Article:

Login

Subscribe To Clinical Trials Advisor